PTCT Q1 2022 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$6B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$149M+26.1% YoY

Gross Profit

$139M93.2% margin

Operating Income

-$87M-58.2% margin

Net Income

-$127M-85.2% margin

EPS (Diluted)

$-1.78

QoQ Revenue Growth

-10.0%

Cash Flow

Operating Cash Flow

-$97M

Free Cash Flow

-$179M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$1.9B

Stockholders' Equity

-$91M

Cash & Equivalents

$144M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$149M	$118M	+26.1%
Gross Profit	$139M	$109M	+27.3%
Operating Income	-$87M	-$98M	+11.8%
Net Income	-$127M	-$129M	+1.5%

Geographic Segments

Non-US

$79M62%

United States

$49M38%